Abstract
Background
The natural course in subjects manifesting normal serum thyroxine (T4), and triiodothyronine (T3), with an elevated thyrotropin (TSH) level demonstrated two distinct outcomes, one progressing to well defined hypothyroidism as expressed by onset of subnormal T4, T3 and a further rise in TSH and the other remaining in the same state. However, thyroid hormone concentrations at the time of diagnosis fail to distinguish between the two groups. Therefore, we examined the influence of alteration in circulating TSH levels on thyroid gland function at the time of diagnosis in subjects with this syndrome to assess the role of pituitary thyroid axis in these different outcomes.
Methods
24 hour 131I thyroidal uptake was determined in 14 men and 3 women manifesting normal T4, T3 and elevated TSH prior to and again after 1) subcutaneous administration of bovine TSH, 10 units daily for 3 days and 2) daily oral administration of L.-triiodothyronine 75 μg for 7 days in a randomized sequence at interval of 4 weeks. Subjects were then followed for up to 16 years to assess the natural course.
Results
Basal 24 hour131I uptake values were with-in the normal range (10–35%) in all subjects and increased on TSH administration and declined following LT3 administration. However, in eight subjects, these responses were markedly lower (< 20%) when compared with the minimum change (50%) noted in normal volunteers. These subjects progressed to manifest hypothyroidism requiring LT4 therapy within two years as reflected by a progressive decrease to subnormal T4 levels with a further rise in serum TSH. The remaining nine subjects, demonstrated normal responses (> 50%) and only one of these became hypothyroid during the follow-up period of 16 years.
Conclusion
All subjects with normal T4 and T3 with elevated TSH do not manifest “subclinical or evolving hypothyroidism”. Two distinct populations seem to exist, one with inhibited pituitary thyroid axis progressing to hypothyroidism or true “subclinical hypothyroidism” at the time of diagnosis and the other with normal pituitary thyroid axis, a state of euthyroidism with “reset thyrostat” at a higher TSH concentration, a state probably persisting for their remaining life span.
Similar content being viewed by others
References
Cooper D.S., Halpern R., Wood L.C., Levin A.A., Ridgway E.C. L-Thyroxine therapy in “subclinical hypothyroidism”: A double-blind, placebo-controlled trial. Ann. Intern. Med. 1001: 18, 1984.
Nystrom E., Ca K., Fager G., Wikkelso C, Lunberg P.A., Lindstedt G. A double-blind cross-over 12-month study of L- thyroxine treatment of women with “subclinical” hypothyroidism. Clin. Endocrinol. (Oxf.) 29: 63, 1988.
Bastenie P.A., Vanhaelst L, Neve P. Coronary artery disease in hypothyroidism: Observation in preclinical myoedema. Lancet 2: 1221, 1967.
Fowler P.B.S., Swale J., Andrews H. Hypercholesterolemia in borderline hypothyroidism: Stage of premyxoedema. Lancet 2: 488, 1970.
Bastenie P.A., Vanhaelst L., Bonnyns L., Neve P., Staquet M. Preclinical hypothyroidism: A risk factor for coronary-heart disease. Lancet 1: 203, 1971.
Evered D.C., Ormston B.J., Smith P.A., Hall R., Bird T. Grades of hypothyroidism. Br. Med. J. 1: 657, 1973.
Tunbridge W.M.G., Brewis M., French J.M., Appleton D., Bird T., Clark F., Evered D.C., Evans J.G., Hall R., Smith P., Stephenson J., Young E. Natural history of autoimmune thyroiditis. Br. Med. J. (Clin. Res.) 282: 258, 1981.
Gordin A., Lamberg B-A. Spontaneous hypothyroidism in symptomless autoimmune thyroiditis: A long-term follow-up study. Clin. Endocrinol. (Oxf.) 15: 537, 1981.
Tibaldi J., Barzel U.S. Thyroxine supplementation for the prevention of clinical hypothyroidism. Am. J. Med. 79: 241, 1985.
Sawin C.T., Chopra D., Azizi F., Mannix J.E., Bacharach P. The aging thyroid: Increased prevalence of elevated serum thyrotropin levels in the elderly. JAMA 242: 247, 1979.
Tunbridge W.M.G., Evered D.C., Hall R., Appleton D., Brewis M., Clark F., Evans J.G., Young E., Bird T., Smith P.A. The spectrum of thyroid disease in a community: The Wickham survey. Clin. Endocrinol. (Oxf.) 7: 481, 197
Lipson A., Nickoloff E.L., Hsiung Has T., Kasecamp W.R., Drew H.M., Shakir R., Wagner H.N. Jr. A study of age-dependent changes in thyroid function tests in adults. J. Nucl. Med. 20: 1124, 1979.
Rosenthal M.J., Sanchez C.J. Thyroid disease in the elderly-missed diagnosis or over diagnosis? West J. Med. 743: 643, 1985.
Bahemuka M., Hodkinson H.M. Screening for hypothyroidism in elderly inpatients. Br. Med. J. 2: 601, 1975.
Atkinson R.L., Dahms W.T., Fisher DA, Nichols A.L Occult thyroid disease in an elderly hospitalized population. J. Gerontol. 33: 372, 1978.
Falkenberg M., Kagedal B., Norr A. Screening of an elderly female population for hypo-and hyperthyroidism by use of a thyroid hormone panel. Acta Med. Scand. 214: 361, 1983.
Rosenthal M.J., Hunt W.C., Garry P.J., Goodwin J.S. Thyroid failure in the elderly: Microsomal antibodies as discriminant for therapy. JAMA 258: 209, 1978.
Rosenbaum R.L., Barzel U.S. Clinical hypothyroidism in the elderly. A preventable disorder? J. Am. Geriatr. Soc. 29: 221, 1981.
Caren P.H., Calazel C, Parra HJ., Hoff M., Loavet J.P. Decreased HDL cholesterol in “subclinical hypothyroidism”: The effect of L-thyroxine therapy. Clin. Endocrinol. (Oxf.) 33: 519, 1990.
Arem R., Patsch W. Lipoprotein and apolipoprotein levels in “subclinical hypothyroidism”. Effect of levothyroxine therapy. Arch. Intern. Med. 150: 2097, 1990.
Kung A.W.C., Pang R.W., Janus E.D. Elevated lipoprotein (a) in patients with subclinical hypothyroidism. Clin. Endocrinol. (Oxf.), 43: 445, 1995.
Kabadi U.M. “Subclinical hypothyroidismn”: Natural course of the syndrome during a prolonged follow-up study. Arch. Intern. Med. 153: 957, 1993.
Kabadi U.M. Normal thyrotrophin response to intravenous thyrotrophin releasing hormone administration: The best index of optimal L-thyroxine therapy in primary hypothyroidism. Postgrad. Med. J. 61: 685, 1985.
Kabadi U.M., Rosman P.M. Lack of influence of aging on hypothalamic pituitary thyroid axis in normal subjects. J. Clin. Exper. Gerontol., 9: 189, 1987.
Wartofsky L, Burman K. Alteration in thyroid function in patients with systemic illness: The “euthyroid sick syndrome”. Endocr. Rev. 3: 164, 1982.
Helfand M., Crapo L.M. Screening for thyroid disease. Ann. Intern. Med. 112: 840, 1990.
Parle J.V., Franklyn J.A., Cross K.W., Jones S.C., Sheppard M.C. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin. Endocrinol. (Oxf.) 34: 77, 1991.
Wood J.M., Gordon D.L., Rudinger A.N., Brooks M.M. Artifactual elevation of thyroid-stimulating hormone. Am. J. Med. 90: 261, 1991.
Helfand M, Crapo L.M. Screening for thyroid disease. Ann. Intern. Med. 112: 840, 1990.
Kabadi U.M., Rosman P.M. Thyroid hormone indices in adult healthy subjects: No influence of aging. J. Am. Geriatr. Soc. 36: 312, 1988.
Vanderpump M.P.J., Tunbridge W.M.G., French J.M., Appleton D., Bates D., Clarks F., Evans J.G., Hasan D.M., Rodgers H., Tunbridges F., Young E.T. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. (Oxf.) 43: 55, 1995.
Mandel S.J., Brent G.A., Larsen P.R. Levothyroxine therapy in patients with thyroid disease. Ann. Intern. Med. 119: 492, 1993.
Roti E., Minelli R., Gardini E., Braverman L.E. The use and misuse of thyroid hormone. Endocr. Rev. 14: 401, 1993.
Baker B.A., Hossen G., Markowitz H. Correlation of thyroid antibodies and cytologic features in suspected autoimmune thyroid disease. Ann. J. Med. 74: 941, 1983.
Wilson R., McKillop J.H., Crocket G.T., Pearson C, Jenkins C, Burns F., Burnett A.K., Thomson J.A. The effect of lithium therapy on parameters thought to be involved in the development of autoimmune thyroid disease. Clin. Endocrinol. (Oxf.), 34: 357, 1991.
Peterson V.B., Mcgregor A.M., Belchetz P.E., Elkeles R.S., Hall R. The secretion of thyrotropin with impaired biological activity in patients with hypothalamic-pituitary disease. Clin. Endocrinol. (Oxf.) 8: 397, 1978.
Faglia G., Bitensky L, Pinchera A., Ferrari C, Paracchi A., Beck-Peccoz P., Ambrosi B., Spada A. Thyrotropin secretion in patients with central hypothyroidism: Evidence for reduced biological activity of immunoreactive thyrotropin. J. Clin. Endocrinol. Metab. 6: 989, 1979.
Beck-Peccoz P., Amr S., Menezes-Ferreira M., Faglia G., Weintraub B.D. Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. N. Engl. J. Med. 312: 1085, 1985.
Horimoto M., Nishikawa M., Ishihara T., Yoshikawa N., Yoshimura M., Inada M. Bioactivity of thyrotropin (TSH) in patients with central hypothyroidism: Comparison between in vivo 3,5,3’-Triiodothyronine response to TSH and in vivo bioactivity of TSH. J. Clin. Endocrinol. Metab. 80: 1124, 1995.
Author information
Authors and Affiliations
Additional information
The data were presented in part at the annual meeting of the Endocrine Society — June 1991 in Washington D.C.
Rights and permissions
About this article
Cite this article
Kabadi, U.M., Cech, R. Normal thyroxine and elevated thyrotropin concentrations: Evolving hypothyroidism or persistent euthyroidism with reset thyrostat. J Endocrinol Invest 20, 319–326 (1997). https://doi.org/10.1007/BF03350310
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350310